The Vetr crowd downgraded its rating on Biogen Inc. (NASDAQ:BIIB) from 4 stars (Buy), issued 26 days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was split, with 50 percent of Vetr user ratings bullish.
The downgrade comes as share price in the biotech found its level around the $315 mark after coming off of a September in which the stock breached $300 for the first time since 2016. Over the course of 2017's third quarter, share price in Biogen increased by more than 25 percent.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
This increased attention also drew some mixed analyst attention, with a Buy initiation from analysts with SunTrust Robinson Humphrey and a downgrade to Market Preform from analysts with Raymond James.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average price target on Biogen is up at $316.39, which is still below the average analyst price target of $329.95. Less than 2 percent of Vetr users are holding BIIB in their watch-lists.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.